Consistent with the observation that glucagon acts on the pancreatic -cells to stimulate insulin secretion via the GLP-1 receptor (GLP-1R) [24,25,26,27], long-term treatment of diet-induced obese (DIO) mice with a biochemically modified water-soluble glucagon improved glucose metabolism with equal efficacy relative to treatment with exendin-4 [23]
But essentially, Medicaids stance parallels Medicare: diabetic use is a mandatory coverage, but obesity use is optional
Additionally, non-heme iron is absorbed in the duodenum, where acidic gastric secretions enhance iron solubility
With Lillys commercial strength and Pharmarons manufacturing support, the drug is expected to become one of the leading players in the oral GLP-1 market
"What happens if the government stops us importing supplies of B12 from Europe?" Wonders Carol
D.et al (2024)